Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Trial Profile

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ReNew
  • Sponsors Merck KGaA
  • Most Recent Events

    • 12 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Aug 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov record.
    • 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top